Ovarian cancer patients need better treatment options. Finding those options has become the life work of UCLA gynecologic surgeon Dr. Sanaz Memarzadeh.
With support from the UCLA Broad Stem Cell Research Center, Memarzdeh is moving ever closer to a clinical trial for a combination therapy that she believes will give hope to women with a particularly dangerous form of ovarian cancer, known as epithelial ovarian cancer.
“So why is it that epithelial ovarian cancer, an aggressive subtype, often recurs despite standard therapy? Our research shows that a pre-existing population of tumor cells is simply resistant to standard chemotherapy treatments. These cells are not only therapy resistant but are also the cancer stem cells that regenerate the tumor and are likely responsible for high rates of relapse,” she wrote in a recent blog post. “This may seem like a daunting problem but our work has uncovered vulnerabilities in these cancer stem cells that can be exploited.”
In her post, “4 Facts About Ovarian Cancer You Should Know & Spread,” Memarzadeh shares information that she encourages others to share as well, such as the statistics and signs of ovarian tumors.
She concludes: “ It’s hard to catch ovarian cancer early, and the treatment options are not as effective as they should be. We can, we must do better.”
Her work is an important step. Learn more about it at G.O. Discovery Lab.